About Scil Proteins
Scil Proteins is a Healthcare company based in Halle (Germany) founded in 1999, and was acquired by Wacker Chemie in June 2014. It operates as an unique Affilin-based proteins are generated and optimized for therapeutic applications. Scil Proteins has raised $32.07 million across 1 funding round from investors including Wacker Chemie and BioNet Pharma. The company has 54 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Navigo Proteins GmbH. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Scil Proteins was established in 1999 in Halle, Germany, within the biotechnology sector. Affilin-based proteins, derived from human scaffolds, are engineered using a proprietary modular platform for therapeutic and non-therapeutic purposes. Operations focus on developing drug conjugates, multi-specific binding molecules, and ligands for partners in pharmaceuticals, biotech, and life sciences. Full ownership is maintained by BioNet Ventures.
- Headquarters Halle, Germany
- Employees 54
- Stage Acquired
- SectorsHealthcare
- Website ww38.scilproteins.com
- Social LinkedIn
- Acquired by Wacker Chemie (Jun 2014)
- Legal Name Navigo Proteins Gmbh
- Annual Revenue$56.91 K (USD)2as on Dec 31, 2015
- Net Profit-$3.93 M (USD)-16as on Dec 31, 2015
- Total Equity Funding$32.07M (USD)
in 1 rounds
- Latest Funding Round$32.07M (USD), Series C
Jun 2010
- InvestorsWacker Chemie
& 1 more
- Employee Count54
- Acquired byWacker Chemie
(Jun 2014)
Funding Insights of Scil Proteins
Scil Proteins has successfully raised a total of $32.07M through 1 strategic funding round. The most recent funding activity was a Series C round of $32.07 million completed in June 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $32.07M
- Total Rounds 1
- Last Round Series C — $32.07M
- First Round $32.07M
(Jun 2010)
- Investors Count 1
All 1 funding rounds of Scil Proteins with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2010 | $32.07M | Series C | – | BioNet Pharma | – |
2 investors in total: 2 institutional.
Investors in Scil Proteins
Scil Proteins has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wacker Chemie and BioNet Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Develops and licenses pharmaceutical programs for various indications through partnerships. | 2003 | bionetpharma.com | Munich, Germany | |
Silicones, polymers, and bio-solutions are manufactured for various industries. | 1914 | wacker.com | Munich, Germany |
Investor details for Scil Proteins
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Scil Proteins
3 dated milestones of Scil Proteins across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Scil Proteins is founded.
- Funding First funding round of $32.1M.
- Exit Acquired by Wacker Chemie.
Competitors of Scil Proteins
Scil Proteins has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Scil Proteins
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Scil Proteins (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Scil Proteins
Scil Proteins was founded in 1999 and raised its 1st funding round 11 years after it was founded.
Scil Proteins is headquartered in Halle, Germany. It is registered at Halle, Sachsen-anhalt, Germany.
Scil Proteins is a funded company, having raised a total of $32.07M across 1 funding round to date. The company's 1st funding round was a Series C of $32.07M, raised on Jun 2010.
Scil Proteins has 54 employees.
Annual revenue of Scil Proteins is $56.91K as on Dec 31, 2015.
Scil Proteins was established in 1999 in Halle, Germany, within the biotechnology sector. Affilin-based proteins, derived from human scaffolds, are engineered using a proprietary modular platform for therapeutic and non-therapeutic purposes. Operations focus on developing drug conjugates, multi-specific binding molecules, and ligands for partners in pharmaceuticals, biotech, and life sciences. Full ownership is maintained by BioNet Ventures.
Scil Proteins's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Scil Proteins has 2 investors. Key investors include Wacker Chemie, and BioNet Pharma.
Scil Proteins operates through Navigo Proteins Gmbh.
Yes. Scil Proteins was acquired by Wacker Chemie in June 2014.